根据多重剥夺指数 (IMD) 衡量，社会经济地位较低与吸烟相关疾病死亡率较高以及癌症筛查接受率较低有关。在这里，我们在 UKLS LDCT 筛查试验中探讨社会经济地位是否会影响单轮低剂量 CT 筛查的有效性，或影响其他死因。IMD 五分位数是根据英国范围内的数据定义的，其中贫困组为定义为较低的两个五分位数（Q1-2），贫困程度较低的定义为 Q3-5。获得了肺癌诊断（中位随访 9.1 年）和死亡原因（中位随访 9.9 年）的随访数据。根据 IMD 组和试验组（CT 或对照）对结果进行比较。更多贫困五分位数的人不太可能回答问卷，但该人群更有可能被 LLP 风险模型选择进行筛查。较低IMD五分位数在肺癌生存方面受益于低剂量CT筛查（HR 1.89，95% CI 1.16-3.08），其受益程度与较高五分位数（HR 1.87，95% CI 1.07-3.26）相同。然而，在较贫困的五分之一人口中，对慢性阻塞性肺病和肺气肿造成的死亡影响更大。虽然 LDCT 对肺癌的筛查效果相似，但对其他吸烟相关疾病（尤其是慢性阻塞性肺病和肺气肿）的死亡率有显着影响主要是在社会经济地位较低的群体中。未来的研究需要确认肺癌筛查如何有益于其他疾病结果。NIHR 健康技术评估计划；国家卫生研究院政策研究计划；罗伊城堡肺癌基金会。© 2024 作者。

Lower socioeconomic status, as measured by the Index of Multiple Deprivation (IMD), is associated with higher rates of smoking-related disease mortality, and with poor uptake of cancer screening. Here we explore whether socioeconomic status impacts the effectiveness of a single round of low-dose-CT screening, or impacts other causes of death, in the UKLS LDCT screening trial.IMD quintiles were defined according to UK-wide data, with the deprived group defined as the lower two quintiles (Q1-2) and the less deprived as Q3-5. Follow-up data was obtained for lung cancer diagnosis (median follow-up 9.1 years) and cause of death (median follow-up 9.9 years). Outcomes were compared based on IMD group and trial arm (CT or control).More deprived quintiles were less likely to respond to the questionnaire, but this population was more likely to be selected for screening by the LLP risk model. Lower IMD quintiles benefitted from low-dose-CT screening in terms of lung cancer survival (HR 1.89, 95% CI 1.16-3.08) to the same extent as upper quintiles (HR 1.87, 95% CI 1.07-3.26). However, there was a bigger impact on deaths due to COPD and emphysema in more deprived quintiles.Whilst LDCT screening benefit for lung cancer was similar, significant impact on the rates of death from other smoking-related diseases, notably COPD and emphysema, was seen primarily in lower socioeconomic groups. Future research is required to confirm how lung cancer screening benefits other disease outcomes.NIHR Health Technology Assessment Programme; NIHR Policy Research programme; Roy Castle Lung Cancer Foundation.© 2024 The Author(s).